52 North Health

52 North Health is a Cambridge-based medtech company on a mission to reinvent the healthcare journey for patients living with cancer. Named after the GPS coordinates of Cambridge, the company was founded in 2018 by a multidisciplinary team of researchers and clinicians from the University of Cambridge. The company's founding insight was that the digitisation of healthcare was creating new risks of health inequality, and that the most powerful innovations were those that improved outcomes for all patients — not just those with access to specialist hospital care.

The company's flagship product, NeutroCheck®, is a low-cost, finger-prick, point-of-care lateral flow device that enables cancer patients undergoing chemotherapy to self-assess their risk of neutropenic sepsis — a life-threatening complication that kills three people in England and Wales every day and sends thousands more to A&E unnecessarily. The accompanying smartphone app uses AI to interpret results and guide clinical decision-making. By enabling reliable at-home monitoring, NeutroCheck® allows high-risk patients to get treatment faster while preventing the half of all A&E visits that are 'false alarms'. 52 North has also adapted its platform for defence use via NATO DIANA, developing ARC™ — a device for detecting acute radiation sickness in emergency scenarios.

52 North Health has raised over $7.8 million across multiple funding rounds, including a £3.6 million Series A in late 2024 led by KHP Ventures and Cedars-Sinai Health Ventures, with participation from Cambridge Enterprise, Cancer Research Horizons, and Macmillan Cancer Support. The company has strategic partnerships with the UK Sepsis Trust and Macmillan Cancer Support, and is preparing to launch NeutroCheck® in the UK, US, and European markets in 2025, with NHS clinical trials at Addenbrooke's Hospital already under way.